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ARTICLE
Evaluation of Drug–Drug Interactions of Rucaparib and 
CYP1A2, CYP2C9, CYP2C19, CYP3A, and P- gp Substrates 
in Patients With an Advanced Solid Tumor
Jim J. Xiao1,*, Dorota Nowak2, Rodryg Ramlau3, Monika Tomaszewska-Kiecana4, Piotr J. Wysocki5, Jeff Isaacson6, Jeri Beltman7, 
Eileen Nash8, Robert Kaczanowski9, Gerhard Arold9 and Simon Watkins10
This phase I study (CO- 338- 044; NCT02740712), conducted in patients with advanced solid tumors, evaluated the effect of 
the poly(ADP- ribose) polymerase (PARP) inhibitor rucaparib on the pharmacokinetics (PK) of caffeine 200 mg, warfarin 
10 mg, omeprazole 40 mg, and midazolam 2 mg (cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, and CYP3A substrates; 
dosed as a cocktail) and digoxin 0.25 mg (P- glycoprotein (P- gp) substrate; dosed separately) without rucaparib and following 
oral rucaparib 600 mg b.i.d. Geometric mean (GM) ratios (90% confidence interval (CI)) of area under the concentration- time 
curve (AUC) from time zero to last quantifiable measurement with and without rucaparib were: caffeine, 2.26 (1.93–2.65); 
S- warfarin, 1.49 (1.40–1.58); omeprazole, 1.55 (1.32–1.83); midazolam, 1.39 (1.14–1.68); and digoxin, 1.20 (1.12–1.29). There 
was limited effect on peak concentration of the substrates (GM ratios, 0.99–1.13). At steady state, rucaparib 600 mg b.i.d. 
moderately inhibited CYP1A2, weakly inhibited CYP2C9, CYP2C19, and CYP3A, and marginally increased digoxin exposure.
Rucaparib (Clovis Oncology, Boulder, CO) is an oral 
poly(ADP- ribose) polymerase (PARP) inhibitor approved by 
the US Food and Drug Administration (FDA) as monother-
apy for the maintenance treatment of adult patients with 
recurrent epithelial ovarian, fallopian tube, or primary peri-
toneal cancer who are in a complete or partial response to 
platinum- based chemotherapy and for treatment of adult 
patients with deleterious BRCA1 or BRCA2 mutation (germ-
line and/or somatic)- associated epithelial ovarian, fallopian 
tube, or primary peritoneal cancer who have been treated 
with two or more chemotherapies.1–3
The drug– drug interaction (DDI) potential of rucaparib 
as a cytochrome P450 (CYP) perpetrator was assessed in 
vitro (Clovis Oncology, data on file). In human liver micro-
somal studies, rucaparib inhibited CYP1A2 and CYP2C19, 
with  inhibition constant (Ki) values of 9.3 and 17.1 μM, 
 respectively. Rucaparib showed mixed inhibition of CYP2C9 
(competitive Ki = 67 μM; uncompetitive Ki = 31.5 μM), as 
well as reversible CYP3A inhibition (half maximal inhibitory 
concentration = 17.2 μM). In a CYP2D6 inhibition assay 
conducted in human liver microsomes, rucaparib showed 
no inhibition of CYP2D6 up to 25 μM. Additionally, rucaparib 
1Clinical Pharmacology and DMPK, Clovis Oncology, Inc., Boulder, Colorado, USA; 2Department of Oncology, West Pomeranian Center of Oncology, Szczecin, Poland; 
3Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland; 4Medical Department, BioVirtus Research Site, Warsaw, Poland; 5Department of 
Oncology, Jagiellonian University – Medical College, Cracow, Poland; 6Biostatistics and Data Management, Clovis Oncology, Inc., Boulder, Colorado, USA; 7Regulatory 
Affairs, Clovis Oncology, Inc., Boulder, Colorado, USA; 8Clinical Operations, Clovis Oncology, Inc., Boulder, Colorado, USA; 9Medical Affairs, PRA Health Sciences, Berlin, 
Germany; 10Clinical Science, Clovis Oncology, Inc., Boulder, Colorado, USA. *Correspondence: Jim J. Xiao, (jxiao@clovisoncology.com)
Received: 16 October 2018; accepted: 19 October 2018; published online on 20 December 2018. doi:10.1111/cts.12600
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Prior studies have described the single-dose and 
steady-state PK profiles of oral rucaparib, a PARP inhibi-
tor; however, no studies have characterized DDIs for ruca-
parib in a clinical setting.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  What, if any, effect does oral rucaparib 600 mg b.i.d. 
have on the CYP enzymes CYP1A2, CYP2C9, CYP2C19, 
and CYP3A, and the P-gp transporter?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  At steady state, rucaparib 600 mg b.i.d. showed mod-
erate inhibition of CYP1A2 and weak inhibition of CYP2C9, 
CYP2C19, and CYP3A as determined by fold increase in 
AUC and/or peak plasma concentration of probe drugs.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY 
OR TRANSLATIONAL SCIENCE?
✔  These findings will provide clinicians with the ability to 
better manage administration of concomitant medications 
for patients who are receiving oral rucaparib 600 mg b.i.d.
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showed concentration- dependent CYP1A2 induction and 
CYP3A4 downregulation in human hepatocytes. Given the 
mean steady- state peak plasma concentration (Cmax) of 
6 μM following rucaparib 600 mg b.i.d., in vivo CYP inter-
action could not be ruled out. Based on results from an in 
vitro transporter interaction study using digoxin as a probe 
substrate across the monolayer of MDCKII cells transfected 
with MDR1, rucaparib is an inhibitor of P- glycoprotein 
 (P- gp), with half maximal inhibitory concentration of 169 μM, 
suggesting potential P- gp inhibition in the gut.
In part 1 (dose escalation phase) of the phase I/II study 
CO- 338- 010 (study 10; NCT01482715), the single- dose 
and steady- state pharmacokinetic (PK) profiles of rucapa-
rib administered orally q.d. (range = 40–500 mg) or b.i.d. 
(range = 240–840 mg) were evaluated.4,5 The PK of rucapa-
rib was linear, with time independence and dose proportion-
ality across all dosages; steady state was achieved following 
7 days of dosing.4,5 Across the dosage levels evaluated, 
 median time to Cmax (Tmax) ranged from 1.5−6 hours; the 
half- life (t1/2) was ~17 hours.
4,5 A high- fat meal caused a 20% 
 increase in Cmax and 38% increase in area under the plasma 
concentration- time curve (AUC), but the effect was not 
 clinically significant based on collective clinical efficacy and 
safety data.2–4,6 Oral rucaparib 600 mg b.i.d. with or without 
food was selected as the recommended phase II dose.4,5
In this study (CO- 338- 044; NCT02740712), rucaparib 
was administered to patients with advanced solid tumors to 
characterize potential DDIs. For evaluation of CYP enzymes, 
four of the five probe drugs in the validated Cooperstown 
5 + 1 cocktail7 were used as substrates, including caffeine 
(CYP1A2), S- warfarin (CYP2C9), omeprazole (CYP2C19), 
and midazolam (CYP3A). Dextromethorphan, a CYP2D6 
probe substrate used in the Cooperstown 5 + 1 cocktail, 
was not included in this study based on results of in vitro 
studies. To test potential interactions with a P- gp trans-
porter, which is not part of the validated cocktail, digoxin 
was dosed separately (24 hours after the cocktail). A simi-
lar staggered digoxin dosing following administration of the 
Cooperstown cocktail has been previously reported.8,9 The 
primary objective of this study was to determine the effect of 
rucaparib at the recommended clinical dose (600 mg b.i.d.) 
on the PK of the selected substrates of CYP1A2, CYP2C9, 
CYP2C19, and CYP3A (as part of a validated cocktail7) 
and P- gp (dosed separately) after a single oral dose of the 
substrates.
METHODS
Patients
Patients were eligible to enroll in the study if they were 
≥ 18 years old, had a histologically or cytologically con-
firmed advanced solid tumor with evidence of measurable 
disease per Response Evaluation Criteria In Solid Tumors 
version 1.1,10 and, in the opinion of the investigator, could 
potentially benefit from treatment with rucaparib. Patients 
must have had a body mass index 18.0–35.0 kg/m2, 
Eastern Cooperative Oncology Group Performance Status 
of 0 or 1, and adequate organ function. All patients enrolled 
in this DDI study had adequate renal function (creatinine 
clearance ≥ 45 mL/min using Cockcroft Gault formula) and 
hepatic function (total bilirubin ≤ 1.5 × upper limit of normal, 
serum albumin ≥ 30 g/L, aspartate aminotransferase and 
alanine aminotransferase ≤ 3 × upper limit of normal). The 
cutoff values were selected to represent the real patient 
populations for the approved indications by the FDA and 
the European Medicines Agency. Patients were excluded 
if they had received chemotherapy, radiation, immunother-
apy, gene therapy, vaccine therapy, angiogenesis inhibitors, 
or experimental drugs within 14 days prior to day 1; had on-
going grade ≥ 1 adverse effects from such treatment per 
Common Terminology Criteria for Adverse Events (ongo-
ing grade 2 nonhematologic toxicity related to most recent 
treatment regimen could be permitted with prior advanced 
approval from the study sponsor); or had prior treatment 
with any PARP inhibitor unless it was not the most recent 
treatment, and it had been discontinued > 3 months before 
the first planned dose of rucaparib. Patients should not be 
on treatment with any of the study probe drugs or strong/
moderate perpetrators (including medicines and herbal 
products) of the tested CYP enzymes or P- gp. Ingestion of 
grapefruit, star fruit, Seville oranges, pomegranate, pom-
elo, or juices from these fruits was not allowed within 7 days 
prior to day 1 and for the duration of the study. Ingestion of 
alcohol or any products containing methylxanthine or caf-
feine (e.g., coffee, black and green tea, cocoa or choco-
late, cola, and energetic beverages) was not allowed within 
72 hours prior to day 1 and for the duration of the study. 
Use of nicotine- containing products was not allowed within 
3 months prior to screening and for the duration of the 
study. Lifestyle restrictions included prohibition of stren-
uous activity, sunbathing, or contact sports from 4 days 
prior to entry in the study site until the end of the study; use 
of precautions against photosensitivity when going out-
side (e.g.,  applying sunscreen, covering exposed skin, and 
wearing a hat and sunglasses); and the practice of highly 
effective methods of contraception (e.g., progesterone- 
only injectable or  implantable contraceptives, intrauterine 
device or system, bilateral tubal occlusion, vasectomy with 
documentation of absence of sperm in ejaculate, and/or 
true, complete  abstinence) for patients of childbearing po-
tential and their partners or postmenopausal women with 
amenorrhea < 1 year (unless postmenopausal status was 
confirmed by follicle- stimulating hormone test).
All patients provided written informed consent. The study 
was approved by the institutional review boards of each insti-
tution and was conducted in accordance with the Declaration 
of Helsinki and the Good Clinical Practice Guidelines of the 
International Conference on Harmonisation.
Study design
This was a phase I, open- label, sequential, DDI study in 
 patients with advanced solid tumors. Patients were  admitted 
and remained at the study sites from day – 1 to day 3 and 
from day 11 to day 14 for dosing and serial PK blood col-
lection (Figure 1). After discharge, the patients returned to 
the sites for outpatient visits on days 4, 5, 7, and 9. Patients 
received a single oral dose of a CYP substrate cocktail of 
caffeine 200 mg, S-warfarin 10 mg, omeprazole 40 mg, 
and midazolam 2 mg (substrates for CYP1A2, CYP2C9, 
CYP2C19, and CYP3A, respectively) on days 1 and 12, a 
single oral dose of digoxin 0.25 mg (P- gp substrate) on days 
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2 and 13, and oral rucaparib 600 mg b.i.d. from day 5 to 
day 16. Midazolam 2 mg was prepared in a solution of 5% 
dextrose in water and provided to patients orally. Vitamin K 
10 mg (warfarin antagonist) was given on days 1 and 12 for 
bleeding prophylaxis; additional doses were given on days 
2 and 13, if needed. The PK was monitored up to 96 hours 
for S- warfarin and 72 hours for the other substrates. Serial 
blood samples were obtained before dosing and at 0.25 
(CYP cocktail only), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 
96 (S- warfarin only) hours after dose of the CYP cocktail 
or digoxin. For rucaparib PK, serial blood samples were 
obtained prior to dosing on days 7, 9, 11, and 12, and at 
0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after dose on 
day 12. For predose (trough) samples, a 20- minute window 
before dosing was allowed; for postdose samples, a time 
window of ± 5 minutes for up to 2 hours, ± 10 minutes for 
3–24 hours, and ± 2 hours for 48–96 hours was allowed.
Probe drugs were administered to patients in the morning 
after an overnight fast of ≥ 8 hours, and fasting continued 
for ≥ 2 hours after administration. Tablets were taken with 
≥ 240 mL water. Water was restricted for 1 hour before and 
after administration.
Genotyping
Genotypes of CYP2C9 and CYP2C19 were determined 
using validated methods for all patients by Genelex (Seattle, 
WA). The genotyping included testing for CYP2C9 alleles 
*2– 6, *8, *11, *13, and *15 and CYP2C19 alleles *2– 10, *12, 
and *17. Absence of a positive test result for CYP2C9 and 
CYP2C19 for all variants were assigned as CYP2C9*1 and 
CYP2C19*1. If identified as poor metabolizers of CYP2C9 
or CYP2C19, patients were excluded from the PK DDI data 
analysis for the respective probes.
PK variables
Cmax and AUC from time zero to the last quantifiable mea-
sure (AUC0-t), were the primary PK parameters analyzed for 
caffeine, S- warfarin, omeprazole, midazolam, and digoxin 
with and without rucaparib treatment. Other PK parameters 
analyzed for the probe drugs included AUC from time zero 
extrapolated to infinity (AUC0-inf), t1/2, and Tmax. AUC0-inf was 
reported if the portion extrapolated from time of last quan-
tifiable measurement to infinity did not exceed 20%. The 
PK parameters analyzed for rucaparib at steady state (ss) 
include trough plasma concentration, Cmax,ss, Tmax,ss, and 
AUCτ,ss, where τ indicates the dosing interval (12 hours) 
at steady state. The PK parameters were calculated using 
noncompartmental analysis from the plasma concentration- 
time data using WinNonlin version 6.3 (Pharsight, Mountain 
View, CA).
Plasma sample analysis
Validated liquid chromatography- tandem mass spectrome-
try methods were used to determine the plasma concentra-
tions of probe drugs (performed by Frontage Laboratories, 
Exton, PA) and rucaparib (performed by Q Squared 
Solutions BioSciences (formerly Advion Bioanalytical 
Laboratories), Ithaca, NY). Details are provided in the Data 
S1.
Safety
Safety and tolerability were assessed through adverse 
event monitoring, clinical laboratory tests, vital sign mea-
sure ments, 12- lead electrocardiogram measurements, 
and physical examination. Adverse events were  monitored 
throughout the study up to 28 days after the last dose of 
 rucaparib and were classified in accordance with the Medical 
Dictionary for Drug Regulatory Activities  classification sys-
tem version 19.011 and graded for severity in  accordance 
with the Common Terminology Criteria for Adverse Events 
version 4.03.12
Statistical analyses
Descriptive statistics for plasma concentrations and PK 
parameters were provided for each probe drug with and 
without rucaparib treatment, including number of patients, 
arithmetic mean, SD, percent coefficient of variation (%CV), 
SEM, minimum, median, maximum, and geometric mean 
(GM) with 90% CI. The primary PK  parameters (Cmax and 
AUC0-t) and AUC0-inf were natural log- transformed before 
assessment with a linear mixed effects model. Treatment 
was used as fixed effect, and subject was used as a ran-
dom effect. Point estimates for the means and point esti-
mates and corresponding 90% CIs for the differences in 
means between the two conditions (with or without ruca-
parib) for each probe drug were obtained from the linear 
mixed effects model and then exponentiated to obtain 
GMs, GM ratios (GMRs), and respective 90% CIs on the 
original scale. The GMRs of AUC and Cmax for probe drugs 
were calculated in the presence vs. absence of rucaparib. 
Individual and summary statistics of concentration- time 
data were collected for rucaparib. Descriptive statistics for 
Figure 1 Study schema. CYP, cytochrome P450.
Day 1, CYP cocktail
Day 2, digoxin
Day 12, CYP cocktail
Day 13, digoxin
Day 5, start
rucaparib 600 mg b.i.d. 
CYP cocktail
Digoxin
Rucaparib
Day –1,
admission
Day 3,
discharge
Day 11,
admission
Day 14,
discharge
Day 16,
end
Days –28 to –2,
screening
Serial blood 
sampling times
61
www.cts-journal.com
Evaluation of drug–drug interactions of rucaparib
Xiao et al.
PK parameters were provided for rucaparib at steady state 
(day 12), including number of patients, arithmetic mean, SD, 
%CV, SEM, minimum, median, maximum, and GM (includ-
ing 90% CI). All statistical analyses were performed using 
SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Patient demographics and study populations
Of the 17 patients enrolled, 17 (100%) were white and 
13 (76.5%) were women. The median age was 55 years 
(range = 40–67 years), and the mean body mass index was 
28.1 kg/m² (SD = 3.07). Patients had the following advanced 
solid tumor (carcinoma) types: ovarian (n = 8; 47.1%), colon 
(n = 4; 23.5%), non small cell lung (n = 3; 17.6%), parotid 
gland (n = 1; 5.9%), and renal cell (n = 1; 5.9%). All patients 
had advanced metastatic disease and variable nodal dis-
ease (where assessable) at study entry.
All 17 patients were included in the PK and safety popu-
lations. One patient (5.9%) withdrew from the study on day 
9 due to treatment- emergent adverse events (TEAEs) not 
considered related to rucaparib; therefore, the DDI analysis 
population included 16 patients (94.1%).
Genotyping
Based on the CYP2C9 genotyping results, two  patients 
(11.8%) were determined to be poor metabolizers (CYP2C9*2/
CYP2C9*3 and CYP2C9*3/CYP2C9*3), and the other pa-
tients were extensive metabolizers (CYP2C9*1/CYP2C9*1) 
or intermediate metabolizers (CYP2C9*1/CYP2C9*2 or 
CYP2C9*1/CYP2C9*3). The PK parameters were calculated 
for all patients, but the two CYP2C9 poor metabolizers 
were excluded from the DDI analysis for S- warfarin. Based 
on the CYP2C19  genotyping results, eight patients were 
rapid metabolizers (CYP2C19*1/CYP2C19*17), six patients 
were extensive metabolizers (CYP2C19*1/CYP2C19*1), and 
three patients were intermediate metabolizers (CYP2C19*1/
CYP2C19*8 or CYP2C19*2/CYP2C19*17). No patients were 
excluded from the DDI analysis for omeprazole. No geno-
typing was done for CYP1A2, CYP3A4, or P- gp, and no 
patient was excluded from the DDI analyses for caffeine, 
midazolam, or digoxin.
PKs
Patients received oral rucaparib 600 mg b.i.d. from day 5 
to day 16. The GM (%CV) Cmax,ss and AUCτ,ss for rucapa-
rib were 2,650 ng/mL or 8.19 μM (57%) and 25,800 h*ng/mL 
(57%) (Table 1), comparable to the exposures observed in 
other studies (Cmax,ss of 6 μM).
4
The CYP cocktail (caffeine, S- warfarin, omeprazole, and 
midazolam) was dosed orally without rucaparib on day 1 
and after the steady state of rucaparib was achieved on day 
12. The GM concentration- time profiles of a single oral dose 
of each substrate in the CYP cocktail without and with ruca-
parib are shown in Figure 2a–d. Probe drug PK parameters 
(Cmax, AUC0-t, AUC0-inf, t1/2, and Tmax) following a single dose 
of the CYP cocktail or digoxin with and without rucaparib 
are summarized in Table 1. Percent of extrapolated AUC for 
S- warfarin was > 20% in 15 of 16 patients and percent of 
extrapolated AUC for digoxin was > 20% in all 16 patients. 
Therefore, no summary statistics of AUC0-inf are reported for 
these two probe drugs, and no DDI analysis was conducted 
based on AUC0-inf.
DDIs
To determine the inhibitory effect of rucaparib on CYP 
 enzymes and P- gp, the GMRs of probe drugs with rucapa-
rib at steady state to probe drugs alone were determined for 
each PK parameter (Table 1, Figure 3). The inhibition effect 
was categorized based on AUC increase of the probe drugs 
as weak (≥ 1.25- fold but < 2- fold), moderate (≥ 2- fold but 
< 5- fold), and strong (≥ 5- fold) per the FDA and European 
Medicines Agency guidance for drug interaction stud-
ies.12,13 In this study, marginal inhibition was  defined as an 
increase of the exposure (Cmax and/or AUC) by > 1- fold but 
< 1.25- fold. Rucaparib had no apparent effect on the Cmax 
of caffeine but moderately increased caffeine AUC from 
time 0 to 72 hours (AUC0-72 h) and AUC0-inf. The Cmax of S- 
warfarin was marginally increased, and the AUC from time 
0 to 96 hours (AUC0-96 h) was weakly increased with ruca-
parib. Rucaparib marginally increased the Cmax of omepra-
zole and weakly increased the AUC0-72 h and AUC0-inf. For 
midazolam, rucaparib marginally increased the Cmax and 
weakly increased both AUC0-72 h and AUC0-inf. Rucaparib 
had no apparent effect on the Cmax of digoxin and margin-
ally increased the AUC0-72 h.
Safety data
In this study, 16 patients (16/17; 94.1%) experienced TEAEs. 
The most common TEAEs were nausea (9/17; 52.9%), 
 dysgeusia (3/17; 17.6%), headache (3/17; 17.6%), urinary 
tract infection (3/17; 17.6%), and vomiting (3/17; 17.6%). 
The  majority of TEAEs were grade 1 or 2; grade 3 coagulop-
athy, hematuria, and hydronephrosis were reported in one 
patient each (1/17; 5.9%). Individual laboratory parameters 
were generally within normal ranges. Additionally, there 
were four cases in which deviations from normal labora-
tory ranges were grade 3 or higher (two cases of low lym-
phocyte count (2/17; 11.8%), one case of elevated alanine 
aminotransferase (1/17; 5.9%), and one case of low serum 
sodium concentration (1/17; 5.9%)). One patient was with-
drawn from the study on day 9 due to adverse events of 
large intestine perforation and large intestinal obstruction 
related to progression of the underlying adenocarcinoma of 
the colon.
DISCUSSION
In vitro data suggest that rucaparib could reversibly 
 inhibit CYP1A2, CYP2C9, CYP2C19, CYP3A, and P- gp at 
 clinical exposure levels in human liver microsomes (Clovis 
Oncology, data on file). Additionally, rucaparib induced 
CYP1A2 and downregulated CYP3A4 in cryopreserved 
human hepatocytes in a concentration- dependent man-
ner (Clovis Oncology, data on file). The potential for com-
plicated DDIs warranted in vivo assessment following 
repeated rucaparib administration at the recommended 
dosage (600 mg b.i.d.).
Cocktail DDI studies allow for an efficient assessment 
of the effect of a perpetrator drug on multiple DDI probe 
drugs. As there are no DDIs among the probe drugs in the 
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cocktail used in this study,7 observed in vivo interactions 
can be interpreted as the effect of the investigated drug on 
individual probe drugs and the corresponding  enzymes. 
On the other hand, there has been limited success in 
drug- transporter cocktail DDI studies due to a lack of 
 validated cocktails, as well as a lack of probe- transporter 
specificity.14,15
In this cocktail DDI study, the Cooperstown 5 + 1 cock-
tail7 was modified to assess the effect of steady- state 
rucaparib on CYP1A2 (caffeine), CYP2C9 (S- warfarin), 
CYP2C19 (omeprazole), and CYP3A (midazolam). 
Dextromethorphan, a probe drug for CYP2D6 that is part 
of the validated cocktail, was not included in this study. 
Digoxin, a P- gp probe drug, is not a part of the validated 
cocktail, and was dosed 1 day after the cocktail. Similar 
staggered dosing schedules were used successfully in 
previously reported studies.8,9
Cocktail DDI studies for oncology drugs can be con-
ducted in healthy subjects8 or patients with cancer.16,17 As 
rucaparib is a PARP inhibitor, and thus clastogenic,18–21 this 
DDI study was conducted in patients with advanced solid 
tumors. Compared with studies in healthy subjects, a study 
in patients with  advanced cancer could allow better DDI 
characterization as this target population may have altered 
CYP activity and PK of the drug under investigation.17
Among all the probe drugs, caffeine, omeprazole, and 
midazolam have relatively short t1/2 values,
7 whereas t1/2 
values are longer for S- warfarin and digoxin. S- warfarin has 
a t1/2 of ~21–43 hours.
22–24 Digoxin has a t1/2 of ~36 hours 
(range = 24–48 hours),25 which can be prolonged in  patients 
Table 1 Summary of plasma pharmacokinetics of probe drugs
PK parameters by probe 
drug Patients, nb
Geometric mean (%CV)a
Ratio (90% CI)Without rucaparib With rucaparib
Caffeine
Cmax (ng/mL) 16 5,980 (30) 5,900 (16) 0.99 (0.90–1.08)
AUC0–72 h (h*ng/mL) 16 57,500 (61) 130,000 (34) 2.26 (1.93–2.65)
AUC0–inf (h*ng/mL) 11 59,300 (76) 152,000 (31) 2.55 (2.12–3.08)
t1/2 (h) 11 7.0 (78) 20.7 (25) —
Tmax (h) 16 0.5 (0.3, 2.0) 1.0 (0.5, 2.0) —
S- warfarinc,d,e
Cmax (ng/mL) 14 721 (20) 759 (20) 1.05 (0.99–1.12)
AUC0–96 h (h*ng/mL) 14 20,300 (26) 30,200 (29) 1.49 (1.40–1.58)
Tmax (h) 14 1.0 (0.5, 3.0) 1.5 (0.5, 3.0) —
Omeprazole
Cmax (ng/mL) 16 1,110 (71) 1,210 (54) 1.09 (0.93–1.27)
AUC0–72 h (h*ng/mL) 16 2,910 (123) 4,510 (116) 1.55 (1.32–1.83)
AUC0–inf (h*ng/mL) 16 2,920 (123) 4,540 (116) 1.55 (1.32–1.83)
t1/2 (h) 16 1.5 (91) 2.3 (91) —
Tmax (h) 16 2.0 (1.0, 3.0) 2.0 (2.0, 3.0) —
Midazolam
Cmax (ng/mL) 16 19.4 (35) 22.0 (54) 1.13 (0.95–1.36)
AUC0–72 h (h*ng/mL) 16 45.4 (65) 63.0 (69) 1.39 (1.14–1.68)
AUC0–inf (h*ng/mL) 16 48.0 (64) 66.5 (67) 1.38 (1.13–1.69)
t1/2 (h) 16 6.8 (41) 7.8 (39) —
Tmax (h) 16 0.5 (0.3, 1.0) 0.5 (0.2, 2.0) —
Digoxind,e
Cmax (pg/mL) 16 1,940 (34) 1,860 (32) 0.96 (0.84–1.10)
AUC0–72 h (h*pg/mL) 16 21,500 (20) 25,900 (27) 1.20 (1.12–1.29)
Tmax (h) 16 1.0 (0.5, 3.0) 1.0 (0.5, 3.0) —
Rucaparib
Cmax,ss (ng/mL) 16 NA 2,650 (57) —
AUCτ,ss (h*ng/mL) 16 NA 25,800 (57) —
Tmax,ss (h) 16 — 2.5 (0.5, 3.1) —
%CV, percent coefficient of variation; AUC, area under the concentration- time curve; AUC0-72 h, AUC from time 0−72 hours; AUC0-96 h, AUC from time 
0−96 hours; AUC0-inf, AUC extrapolated from time 0 to infinity; AUCτ,ss, AUC over a dosing interval τ (12 hours) at steady state; CI, confidence interval; Cmax, 
peak plasma concentration; Cmax,ss, Cmax during a dosing interval at steady state; CYP, cytochrome P450; DDI, drug– drug interaction; NA, not applicable; 
PK, pharmacokinetics; t1/2, terminal half- life; Tmax, time of maximum plasma concentration.
aFor Tmax, data are reported as median (minimum, maximum). 
bOne patient (5.9%) withdrew from the study on day 9 due to treatment- emergent adverse 
events not considered related to rucaparib; therefore, DDI was only analyzed in 16 patients (94.1%). cTwo patients (11.8%) were determined to be poor me-
tabolizers of CYP2C9 per genotyping and were excluded from the DDI analysis for S- warfarin. dAUC0-inf is not reported because percent of extrapolated AUC 
was < 20% for ≤ 1 patient. eThe t1/2 is not reported due to uncertainty in the reliability of t1/2 estimation.
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with impaired renal function. The long t1/2 values would 
mandate a long PK sampling period in order to capture 
the complete PK profiles (e.g., 5 × t1/2). However, practical 
limitations had to be considered, and in this  rucaparib DDI 
study, PK sampling periods of up to 96 and 72 hours were 
implemented for S- warfarin and digoxin, respectively. These 
were considered justifiable durations, as a study design with 
a PK sampling period of 5 × t1/2 would have required the 
DDI assessment to be ≥ 27 days (vs. 16 days in this study). 
In the event of CYP2C9 or P- gp inhibition, the t1/2 and the 
ideal PK sampling period would be even longer. Excessively 
long PK sampling could have negatively affected patient 
enrollment, delayed continuous rucaparib treatment (offered 
to patients who completed the DDI portion of the study), 
increased the risk of an unstable baseline, or confounded 
the DDI results in this single- sequence crossover DDI study. 
Published PK simulations indicate that the terminal t1/2 and 
AUC0-inf can be reliably estimated with a PK sampling period 
of ~2 × t1/2, and clinical DDI studies with relatively short but 
adequate PK sampling periods for S- warfarin and digoxin 
have been reported. For example, the Cooperstown 5 + 1 
cocktail was validated using a 96- hour PK sampling period 
for S- warfarin.7 In a pazopanib DDI study, S- warfarin PK was 
monitored up to 96 hours.17 In a cocktail DDI study of tipra-
navir and ritonavir, a 72- hour sampling period was applied 
for both S- warfarin and digoxin.8
Figure 2 Arithmetic mean (SD) plasma concentration- time profiles for (a) caffeine, (b) S- warfarin, (c) omeprazole, (d) midazolam, 
and (e) digoxin administered with (blue line) and without (red line) rucaparib. *Following the caffeine dose on day 1, 9 of the 16 
evaluable patients had caffeine concentrations lower than the quantification limit at 72 hours postdose. One subject had a higher than 
expected concentration at the same time point, presumably due to incidental caffeine intake, contributing to an apparent spike in the 
mean caffeine pharmacokinetic profile. The presumed incidental caffeine intake in this one patient had no impact on CYP1A2 DDI 
assessment based on Cmax and AUC0-inf. AUC0-inf, area under the concentration- time curve extrapolated from time 0 to infinity; Cmax, 
peak plasma concentration; DDI, drug–drug interaction.
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Genotyping of CYP2C9 and CYP2C19 was conducted as 
part of this study. Two patients were poor metabolizers of 
CYP2C9 and were excluded from the S- warfarin DDI anal-
ysis. For these two patients, the day 12 to day 1 AUC0-96 h 
ratios were 1.45 and 1.58, respectively, consistent with the 
GMR of 1.49 for the other 14 patients. The reason for the 
apparent CYP2C9 inhibition in the poor metabolizers is 
unknown; however, it fell within the expected intrasubject 
PK variability given the weak inhibition. Data from the two 
CYP2C9 poor metabolizers did not impact the conclusion 
that rucaparib is a weak inhibitor of CYP2C9. No other 
 genotyping was conducted in this study because different 
genotypes are not believed to account for the majority of 
activity variability for CYP1A2,7,17 CYP3A4,7,26 or P- gp8 in 
such studies.
Caffeine, S- warfarin, omeprazole, and midazolam are all 
sensitive in vivo index substrates (i.e., they are associated 
with a > fivefold increase in AUC when coadministered with 
a strong CYP inhibitor). A specific and sensitive index P- gp 
probe drug has not been identified in in vivo DDI studies.12,13 
Nevertheless, digoxin is a widely used P- gp probe sub-
strate27,28 and has a narrow therapeutic window; therefore, 
digoxin was used in this study as an in vivo P- gp probe drug.
In general, the observed rucaparib DDIs were limited in 
magnitude (Table 1, Figure 3). A limited effect of rucapa-
rib on Cmax was observed for all probe drugs, with mean 
GMR ≤ 1.13. This is clinically informative because CYP3A 
and P- gp have been reported to play a role in the intestinal 
absorption of midazolam and digoxin, respectively.29,30 For 
caffeine, omeprazole, and midazolam, AUC0-inf GMRs were 
2.55, 1.55, and 1.38, respectively, suggesting moderate 
(≥ 2- fold to < 5- fold) inhibition of CYP1A2 and weak (≥ 1.25- 
fold to < 2- fold) inhibition of CYP2C19 and CYP3A. For S- 
warfarin and digoxin, truncated AUCs were calculated. The 
GMR (90% CI) of S- warfarin AUC0-96 h was 1.49 (1.40–1.58), 
and the GMR (90% CI) of digoxin AUC0-72 h was 1.20 (1.12–
1.29). These results suggest weak inhibition of CYP2C9 and 
marginal effect on digoxin PK.
The most common TEAE of any grade in this study was 
nausea, experienced by more than half of the patients. In 
this small study population, reported TEAEs were consistent 
with those observed in other studies of rucaparib.3,4,6,31
In summary, results from study CO- 338- 044 indicated 
that at steady state following 600 mg b.i.d. dosing, rucapa-
rib moderately inhibited CYP1A2, weakly inhibited CYP2C9, 
CYP2C19, and CYP3A, and showed marginal effect on  P- gp. 
Patients should be appropriately monitored, and  dosage 
adjustments should be considered for CYP1A2, CYP3A, 
CYP2C9, and CYP2C19 substrates, particularly for medi-
cines with a narrow therapeutic index, if clinically indicated.
Supporting Information. Supplementary information  accompanies 
this paper on the Clinical and Translational Science website (www.
cts-journal.com).
Data S1. Supplementary methods.
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